"Moderna's Cancer Vaccine and Keytruda Combo Shows Promising Results in Melanoma Trial"

Moderna's stock surged by 14% after the announcement that its personalized cancer vaccine, developed in collaboration with Merck, reduced the risk of late-stage melanoma by 49%. The company is also working on bringing more vaccines to market, including one for RSV in 2024 and a flu vaccine in 2025. Moderna's CEO, Stéphane Bancel, will personally oversee commercial operations until 2025, aiming to expedite decision-making processes and strengthen customer relationships. The company has a strong pipeline with 40 products in development, and Wall Street expects its flu, RSV, and COVID-19 vaccines to contribute to a $100 billion portfolio.